Samsung Bioepis Presents Three Abstracts from its Ophthalmology Biosimilar Portfolio for Neovascular Age-Related Macular Degeneration at AAO 2022
Shots:
- The company highlighted the results from its ophthalmology biosimilar portfolio. In a 32wk. interim analysis from the P-III study, SB15 a proposed biosimilar to Eylea showed equivalent efficacy & comparable safety, immunogenicity & PK profile over reference aflibercept in nAMD
- The post-hoc analysis from the P-III study of SB11, a biosimilar to Lucentis showed a low immunogenicity profile with no correlation b/w immunogenicity and clinical outcomes
- In other post-hoc analyses of the P-III study of SB11 showed that baseline age, BCVA, and CST were determined to be predictive of visual acuity & anatomical outcomes, similar results were shown from a post-hoc analysis of multiple trials along with an equivalent clinical efficacy
Ref: Globe Newswire | Image: Samsung Bioepis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
